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There are many challenges to the process of translating the knowledge gained in the laboratory into new clinical
approaches that can meet the needs of patients, clinicians and the wider community. We describe here an initiative
that has borrowed concepts and principles from participatory research to produce a new process embedded in a
cancer center aiming to facilitate translational research and overcome the three translational roadblocks. The
centre-wide project named Personal Response Determinants in Cancer Therapy (PREDICT) operates with the
support of the centre’s leadership, staff, volunteers and patients to contribute to current and future cancer research
successes. We describe the different phases of the project, the current structure and lessons learned during its
evolution, highlighting how PREDICT contributes to translational research and its linkage to participatory research
concepts. Despite the contextualized nature of the PREDICT initiative, we believe that the framework developed for
the project has the potential to help other clinical centers to overcome the translational research roadblocks.
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The pursuit of translational research has historically
been dependent on collaboration and communication
between disciplines. The “bench to bedside” concept,
harnessing knowledge from basic sciences to produce
“new approaches for prevention, diagnosis and treatment
of diseases” in clinical settings [1] implies a connection
between basic scientists and clinicians [2]. But the
strength of this connection is sometimes tenuous and
the US Institute of Medicine has identified two “transla-
tional blocks” in the undertaking of clinical research:
(T1) “the transfer of new understandings of disease
mechanisms gained in the laboratory into the deve-
lopment of new methods for diagnosis, therapy, and pre-
vention and their first testing in humans” and (T2) “the
translation of results from clinical studies into everyday
clinical practice and health decision making” [1,3]. A
third roadblock has more recently been defined: “the
gap between knowledge need and discovery”: the inte-
gration between needs identified by patients, commu-
nity, clinicians, governments and organizations and the
work undertaken by scientists and researchers during the* Correspondence: pwatson@bccancer.bc.ca
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in any medium, provided the original work is pdiscovery process [4]. It has become a widely stated ‘dogma’
that there is an urgent need for more effective strategies for
pursuing translational and clinical science [5-7].
Even though the challenges of translational research are
widely recognized, conceptual frameworks and methods/
tools to address these issues are still being developed
[1,6-8]. Applying participatory research methods and
principles to translational research has been identified as a
promising approach to overcome the “translational road-
blocks” [6]. Hebert et al. [8] argue that community-based
participatory research, translational research and interdis-
ciplinary research share both philosophical underpinnings
and practical means for applying and sharing knowledge
and techniques. Engaging multiple disciplines including
academic and non-academic partners where each one
contributes their expertise from the initiation of the
research design phase can be beneficial to foster owner-
ship, capacity building and empowerment of academic
and non-academic partners [6,9]. Riley et al. [10] high-
lights that, although broad stakeholder engagement may
seem counterintuitive as a strategy to speed research, in-
vestment in this area has the potential to improve re-
cruitment, make the activity and the outcomes of
research more relevant to more stakeholders andOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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practitioners [10].
In 2006, the British Columbia Cancer Agency –
Vancouver Island Centre (BCCA - VIC) initiated a centre-
wide project built on the ideas and energy of clinical and
health care staff, borrowing principles of participatory re-
search and aiming to address the challenges posed by
expanding translational research. Details of the size and
scope of this health care facility are available from our
website (www.bccancer.bc.ca) but briefly, approximately
600 staff and volunteers at the center provide care and re-
search opportunities to about 4,000 new patients each
year. The project, endorsed by the centre’s leadership,
created an environment where all staff, volunteers and
patients contribute to current and future cancer research
successes. This “Personal Response Determinants in
Cancer Therapy” (PREDICT) project has contributed not
only to the engagement of patients in the research process
but also has transformed the way clinical research is con-
ducted at the VIC. We describe here the PREDICT project
as a model to overcome the three “translational blocks” by
improving patient care and engaging staff and patients in
research as part of routine clinical practice.
Our model
Design phase
In 2005, an opportunity to create a new model for the con-
duct of clinical research within which all staff and new pa-
tients could participate to improve future clinical care, was
identified by a group of researchers at VIC and endorsed
by the centre’s leadership. PREDICT was initially funded
by a start-up grant from a government funded foundation
which was matched by funding from a philanthropic foun-
dation. The project was named ‘Personal Response Deter-
minants In Cancer Therapy’ project (PREDICT) to convey
a focus on enabling research focusing on aspects such as
the tumour and its relation to treatment outcomes to
encompass the patient-centered side of the cancer prob-
lem (i.e. patient factors such as biological, psychosocial
and societal), by emphasizing the patient’s key role through
participation, as part of a solution. The PREDICT model
would evolve to have two components: a “permission to
contact” mechanism, asking participants for permission to
be contacted in the future for research; and a biobank
component, collecting and storing blood samples of
participants for future research. The research team, now
re-named the PREDICT Steering Committee requested
expressions of interest to all staff disciplines to join the
PREDICT Design Team. The start-up grant provided
backfill funding to the design team during the design
phase. Ten staff members were selected to be members of
the Design Team based on degree of experience working
with patients, diversity of discipline or other qualities such
as knowledge, ability and leadership that would facilitatean efficient team. Members of this team included a
Change Management Consultant (who had been enrolled
at the outset to assist with the organizational trans-
formation), a Clinical Research Coordinator, a Research
Phlebotomist, an Administrative Assistant, a Clerical
Supervisor, a New Patient Clerk, a Nursing Supervisor, a
Clerk, a Volunteer, a Registered Nurse and a Radiation
Therapist. This team met for a two day workshop at the
beginning of the project where they listened to overall
goals envisaged by the steering committee, and then inde-
pendently discussed the scope of design team, deliverables,
and timelines as well as allocated responsibilities. The
design team met weekly to bi-weekly as required from
March to June 2006 and created an outline for the PRE-
DICT process, making decisions about who would be
approached, when and how to approach potential par-
ticipants, consent, obtain a blood sample and re-contact
patients after consenting. They sought feedback from col-
leagues and evaluated the process in the clinical setting by
participating in a mock trial run.
Ethics approval for an initial pilot phase was obtained in
November 2006. This approval followed an extended
period of discussions around preliminary proposals with
the University of British Columbia-BCCA Research Ethics
Board (REB) that improved the final protocol design.
Pilot study
In the project, new oncology patients are invited to par-
ticipate at the time of their first appointment at the
clinic. Patients who choose to enroll become research
participants who agree to be contacted in the future
by other specific studies related to cancer research
(PREDICT’s “permission to contact” component) and
also agree to the collection and storage of a blood
sample (PREDICT’s biobank component). The project’s
commitment is that this blood sample will be used for
research into cancer, causes of cancer, cancer treatments
or the effects of treatments. In January 2007, a four-
month pilot study, was launched to test the feasibility,
refine the processes, and document any potential diffi-
culties of PREDICT. Two to four clinics per week were
involved in this phase to identify and approach 100
eligible patients for their participation in PREDICT. Pa-
tients were asked to provide a blood sample to be stored
and used for research (anonymised biological samples)
as well as to grant a ‘permission to be contacted’ (PTC)
by future research studies (PREDICT stores the BCCA
registration number only in its database. This number
allows the linkage to the Cancer Agency Information
System, a robust and secure platform that stores demo-
graphics, clinical and treatment data of cancer patients).
After further REB review, a second phase of the pilot
was implemented in May 2007. Over the next 6 months,
PREDICT was gradually expanded to all 20 clinics at
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consented participants in phases 1 and 2.
As an opportunity for staff to become involved and
engaged in the project, change management initiatives
were implemented throughout the early phases of the
project. For example; the involvement of care aids in the
process of paging PREDICT personnel when an eligible
patient is available to be approached has added efficiency
to the consenting step. REB approval was obtained to
proceed from the pilot phase in July 2008 and PREDICT
has been operating as a full centre-wide program since
this time.
The PREDICT process
All new patients are potential participants of PREDICT.
Potential participants are eligible if:
 They are a new patient to the BCCA-VIC.
 Their cancer diagnosis has been confirmed.
 They are 19 years of age or older.
 They fully understand the study and give their
informed consent to participate as demonstrated by
signing the consent form.
Potential participants are not eligible if:
 They are a new patient referred to the BCCA-VIC
but do not have a confirmed diagnosis of pre-cancer
(for example in-situ cancer) or invasive cancer.
 They have already started chemotherapy or
radiation treatment for their in-situ or invasive
cancer. If they are already on hormone therapy, they
are still eligible.
 They are 18 years of age or younger.
 They are not competent to provide informed
consent.
At the time of the first appointment at VIC patients
are flagged and approached by a research intern for con-
senting. At the consenting interview they learn details
about the project including the fact that their bloodTable 1 PREDICT accrual for phase I and II of the pilot
stage
Eligible Approached Consented Declined Deferred
Phase 1
n 104 97 93 3 1
% - 93% 96% 3% 1%
Phase 2
n 963 699 617 37 45
% - 73% 88% 5% 7%
Eligible: patients who meet the eligibility criteria; Approached: patients that
were approached and offered PREDICT; Consented: patients that were offered
PREDICT and consented to participate; Declined: patients that were offered
PREDICT and did not consent to participate; Deferred: patients that chose to
delay their decision.samples will be anonymised and that they will not receive
information about study findings. Since the inception of
PREDICT, there have been over 16,000 eligible new pa-
tients at the VIC and 53% (n = 8751) have been ap-
proached by PREDICT. The reasons for eligible patients
not being approached are systematically recorded. The
most common reason has been “health care decision”
(63%), meaning that the physician or nurse deemed that it
was not appropriate to approach the patient due to
physical and/or psychosocial issues. Other reasons include
“deferred/missed” (25%), “no show” (1%) and “other”
(11%). Patient acceptability and engagement remains high
with 95% of all approached eligible patients choosing to
participate in the PREDICT project (Figure 1).
A series of standard operation procedures (SOPs)
guide the clinical and laboratory activities. A governance
structure was created to facilitate and ensure an ethically
sound process to enable translational research. To fa-
cilitate the use of biospecimens and permission to con-
tact collected by PREDICT, an Access Committee that
accepts and reviews REB approved applications to use
these data was formed and specific SOPs were created to
guide governance and access/release of materials.
The PREDICT governance
The PREDICT design has evolved with time to address
the staff, patient and organizational needs. The current
governance structure includes:
a) Management Committee, (7 individuals meeting 4–6
times per year) responsible for monitoring monthly
accrual, personnel and general operations of the
PREDICT project;
b) Operations Committee, (4 individuals meeting
monthly) a sub-group of the Management committee
responsible for running daily activities within the
project;
c) Access Committee, (9 individuals meeting every
time PREDICT receives an application) responsible
for analyzing and approving or rejecting requests for
sample and/or data release direct to PREDICT;
d) Oversight Committee, (14 individuals meeting 6–10
times per year) a VIC committee responsible for
strategic decisions related to research at our centre
and deployment of philanthropic support. PREDICT
reports on major accomplishment and
organizational changes to this committee 2–3 times
a year.
With the involvement of these committees, PREDICT
supports research conducted by (1) academics affiliated
with the BC Cancer Agency and university institutions
who are funded by academic sources and (2) academics
sponsored and funded in whole or in part from industry
Figure 1 Patient engagement in PREDICT remains high. Accepted: patients that were offered and consented to participate in PREDICT;
Declined: patients that were offered PREDICT and did not consent to participate; Take-home: patients that were offered PREDICT, have taken the
consent home and have not consented or declined participation; Unknown: patients that were offered PREDICT, have not consented or declined
or taken the consent home.
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data requires a formal application and approval process
for all users. To date, 20 research projects have been sup-
ported by PREDICT. These include but are not limited to
studies in the areas of Prostate Cancer, Breast Cancer,
Colorectal Cancers, Melanoma, and Skin Cancer. The
project relies on philanthropic support combined with
partial cost recovery for operational expenses through
user fees to maintain its activities.
Central to staff involvement in PREDICT is the involve-
ment of a ‘Research intern’ to facilitate the consent
process with potential participants: requesting permission
to contact and blood specimen data. Research interns are
trainee individuals who have already obtained a science
undergraduate degree and are applying for higher training
towards a career in a health-related discipline. Staff at all
levels are directly involved in the oversight and training of
these individuals within the clinic as they respond to re-
ferrals, and so contribute directly to the project. Thirteen
individuals have been trained through the PREDICT pro-
ject over the last 6 years: five are currently enrolled in
medical school, four have completed/are enrolled in other
professional schools (nursing, occupational therapy, edu-
cation), two have pursued graduate studies and one iscurrently applying for dentistry school (we lost contact
with one research intern).
As a way of fostering collaborative research partnerships
and enhancing public trust in clinical and translational re-
search, PREDICT reports on their activities regularly not
only to the Oversight Committee but also to staff by pre-
senting results and proposed organizational changes at
staff meetings. We have recently developed an online
newsletter, to be sent to staff twice a year as an additional
aid to disseminate our successes and engage personnel. In
addition, through our presence in the clinic, staff is
reminded that there is an open communication channel
between PREDICT operations and staff and many sugges-
tions have been brought forward directly to members of
the committee.
Discussion
There are many challenges to the process of translating
the knowledge gained in the laboratory into new clinical
approaches that can meet the needs of patients, clinicians
and the wider community. A key part of a strategic
solution to overcome these challenges is to foster collabor-
ation and communication between disciplines and bet-
ween the public and scientists. We have described an
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participatory research to produce a new process embed-
ded in a center that overcomes the three major road
blocks to translational research: (T1) “the transfer of new
understandings of disease mechanisms gained in the
laboratory into the development of new methods for diag-
nosis, therapy, and prevention and their first testing in
humans”; (T2) “the translation of results from clinical
studies into everyday clinical practice and health decision
making” - [1,3] and (T3) “the gap between knowledge
need and discovery” [4]. More than 7 years after its ini-
tiation, PREDICT is still a centre wide program involving
clinicians, basic scientists, leaders and core staff (nurses,
care aids, therapists, physicists, radiation and medical on-
cologists, administrative and clerical staff ), all working to-
gether to achieve a common research goal while providing
cancer care.
In order to address the organizational issues faced by
translational research Woolf et al. [9] indicated that
adequate infrastructure is key. Zerhouni [5] noted that
resources and databases that have the ability to meet the
specific needs of researchers are imperative to enhance
the speed of research. PREDICT also encompasses a bio-
bank that consists of a population-based patient cohort in-
cluding biological specimens, permission to contact and
the ability to link to clinical outcomes data from consen-
ting participants. By using an ethically sound governance
structure in a research driven cancer facility, the
PREDICT project has created the infrastructure that not
only facilitates translational research but can also speed
the process of addressing specific research questions.
The Access Committee has become instrumental in ma-
king this process possible. Partnering with academic re-
searchers locally, nationally and internationally, PREDICT
has been able to support over 20 research projects with
samples, data or permission to contact information.
Through this partnership PREDICT contributes to ad-
dressing the first translational research road block: “the
transfer of new understandings of disease mechanisms
gained in the laboratory into the development of new
methods for diagnosis, therapy, and prevention and their
first testing in humans” [1,3].
Cargo and Mercer [8] identified that participation from
the initiation of the research planning process was an im-
portant factor in commitment to the research process.
Schmittdiel et al. [6] suggests that engaging in collabora-
tive partnerships and investing in long-term relationships
are participatory research methods that may contribute to
overcoming the second translational research road blocks:
“translation of results from clinical studies into everyday
clinical practice and health decision making” [1,3]. Align-
ing with these participatory research principles, the
PREDICT project successfully engaged an interdisciplin-
ary team from the commencement of the design process.In addition, PREDICT maintains a strong presence in the
clinic, with staff who are on the front-line of direct patient
care involved in PREDICT governance and daily activities.
We argue that our front-line approach is effective in en-
gaging staff and consolidating a long-term relationship
that contributes not only to the PREDICT platform sus-
tainability but also may influence their engagement in
other research activities. Some of the PREDICT processes
such as the involvement of care-aids in triggering the con-
sent interview are currently being adopted by other re-
search teams in our centre.
PREDICT has also contributed to overcoming the
third translational research roadblock: “the gap between
knowledge need and discovery”. An empirical validation
of this claim is not possible at this time however, some
evidence of PREDICT bridging this gap already exists:
patients with colorectal cancer contacted through the
PREDICT project suggested the need for more investiga-
tion in the area of physical activity. With the support of
PREDICT, a feasibility study led by investigators from
our centre (testing circuit-based activities for people
with colorectal cancer) was conceptualized, developed
and completed. Currently a randomized clinical trial
built on the results of the feasibility study and funded by
a national grant is accruing participants. We recognize
that formulating new research questions based on the
results of a previous research project is not a new con-
cept. What is impressive, however, is the speed of the
process: within the short time-frame of three years all
these activities have happened and the group estimates
that a new physical activity program will be launched for
all colorectal cancer patients in the clinic next year.
PREDICT has been directly involved in participants’
accrual and health care providers’ engagement in the
project.
Lessons learned
The PREDICT project has evolved considerably since its
conceptualization in 2006. During these seven years we
have learned many lessons that had an impact on this
process:
 The role of PREDICT personnel evolved as staff and
processes changed in the clinic. A PREDICT
assistant was responsible for obtaining written
consent and collecting blood at the first stages of
the project. With a new phlebotomy service being
offered in the clinic, the role was modified and
participants were directed to the new service after
consenting.
 After changing the PREDICT assistant role to
exclude phlebotomy duties, the Steering Committee
identified the opportunity of training graduates from
undergraduate programs to fulfill the revised role.
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end of 2007.
 The number and role of the PREDICT research
interns also changed with time and maturity of the
project. It started with one person responsible for
consenting and blood processing, evolved to two
people each one dedicated to either blood
processing or consenting, then two people sharing
both tasks and now, with the changes in blood
processing (discussed below), we have one person
responsible for both tasks again.
 PREDICT initially processed and stored serum,
plasma and buffy coat from all blood samples
collected. After the first five years, storage space
became limiting and funding for two interns became
difficult to secure. In 2012 PREDICT started
processing and storing buffy coat only in an REB
approved protocol thus reducing time and storage
space requirements.
 The “permission to contact” component of
PREDICT became a very important and valued
resource. 25% of all PREDICT applications (research
studies interested in accessing PREDICT) have
principally focused on this feature of the project and
have not requested access to any blood sample,
while others have valued both the PTC and the
associated blood sample.
 The importance of the design team should not be
underestimated. The group was crucial to maintain
the collaborative focus of the project from the
outset. Although staff has been proactive and made
suggestions directly to PREDICT staff after the
design team was dissolved (in 2008), we are now
discussing the possibility of re-engaging the design
team to address new operational issues as a way of
re-emphasizing the participatory feature of
PREDICT.
 The research intern is the only dedicated PREDICT
staff position. All the committee(s) members have
other clinical and or research duties. Although this
can be viewed as an asset as PREDICT processes are
part of the daily staff activities we perceive it as a
challenge as well. A dedicated coordinator to
support promotion of PREDICT and its availability
to researchers outside our organization and to
handle the gradual (and more rapid if successful
with promotion) increase in number of research
applications is desirable at this point. However,
expanding PREDICT staff has budget implications
and funding is still an issue.
Final comments
Despite the contextualized nature of the PREDICT initia-
tive, its model can be transferred to other out-patientclinic settings. We have created setup documentation,
templates, and provide assistance to enable other centers
to establish similar platforms (www.biobanking.org). In
early 2013, PREDICT celebrated the launch of the pro-
gram at the BCCA - Sindi Ahluwalia Hawkins Centre for
the Southern Interior. Transferability of the model will
however depend on many factors such organizational
structure, leadership endorsement and funding. Never-
theless we believe that the framework developed for the
PREDICT project has the potential to help scientists,
clinicians and the public to overcome the translational re-
search roadblocks.
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